Head-To-Head Review: Eyepoint Pharmaceuticals (NASDAQ:EYPT) vs. CorMedix (NASDAQ:CRMD)

CorMedix (NASDAQ:CRMD) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for CorMedix and Eyepoint Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0	2	7	0	2.78
Eyepoint Pharmaceuticals	1	6	4	0	2.27

CorMedix presently has a consensus price target of $15.00, indicating a potential upside of 106.61%. Eyepoint Pharmaceuticals has a consensus price target of $25.70, indicating a potential upside of 715.87%. Given Eyepoint Pharmaceuticals’ higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than CorMedix.

Risk & Volatility

CorMedix has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.

Profitability

This table compares CorMedix and Eyepoint Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

Insider and Institutional Ownership

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares CorMedix and Eyepoint Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71 million	1.82	$163.05 million	$2.14	3.39
Eyepoint Pharmaceuticals	$31.37 million	8.66	-$231.96 million	($3.74)	-0.84

CorMedix has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Summary

CorMedix beats Eyepoint Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.